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Abstract 
Survival analysis incorporates various statistical methods specific to data on time until an event of 
interest. Whilst the event is often death, giving rise to the phrase ‘survival analysis’, the event might 
also be, for example, a reoperation. As such, it is sometimes referred to as time-to-event analysis. 
Censoring sets survival analysis apart from other analyses: at the end of the follow-up period, not all 5 
subjects have experienced the event of interest, and some subjects may drop out of the study prior to 
completion. Survival data for a group of subjects is usually visualised by the Kaplan-Meier estimator, 
representing the probability of a subject remaining free of the event during follow-up. 
There are several methods to compare survival between study groups, for example treatment 
arms, including the log-rank test and the Cox proportional hazards model. The log-rank test is an 10 
unadjusted nonparametric method, whereas the Cox proportional hazards model allows comparison 
while adjusting for multiple covariates. A principal assumption of the Cox proportional hazards model 
is that the relative hazard stays constant over time—so-called proportionality. Specific methods exist 
for comparison of survival to the general population. This article describes the fundamental concepts 
every cardiothoracic surgeon should be aware of when analysing survival data and are illustrated with 15 
a clinical example. 
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Introduction 
Survival analysis is of great importance for many medical specialties, including cardiothoracic 
surgery. It helps clinicians to provide valuable prognostic information; for example, on the best 
treatment option for patients with coronary artery disease (CAD) when deciding between Percutaneous 25 
Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG). 
A myriad of statistical methods is available when examining survival data. Those most 
commonly utilised in cardiothoracic research include the Kaplan-Meier estimator, log-rank test, and 
the Cox proportional hazards regression model [1-3]. To-date, the original papers by Kaplan and 
Meier and Cox are ranked the 11th and 24th most cited papers of all time in the scientific literature, 30 
demonstrating the reach of the survival analysis methodology [4-6]. It is important for cardiothoracic 
surgeons to understand the fundamentals of these methods in order to adequately appraise and conduct 
survival analyses. Here, distinguished features of survival data are presented and the statistical 
methods most frequently used are discussed. To illustrate, this article includes a clinical example and 
describes the reporting standards for publishing survival analyses in the European Journal of Cardio-35 
Thoracic Surgery (EJCTS) and Interactive Cardiovascular and Thoracic Surgery (ICVTS). 
 
Important aspects 
Censoring. Censoring means that the time to the event of interest cannot be determined. This 
commonly occurs when a subject drops out of the study or does not experience the event before the 40 
study follow-up period is completed [7, 8]. The aforementioned examples are known as right-
censoring. Censoring can also be classified as a left- and interval-censoring. For example, if the event 
of interest was myocardial infarction (MI) after CABG, and the subject did not have a MI at 1-year 
follow-up, but did have a silent MI (pathological Q-waves on the ECG) at 2-year follow-up without 
the exact date of the event, then the event time is interval censored, as we do not exactly know when 45 
the MI occurred, except sometime between the two clinic visits. 
Defining the event of interest. It is important to clearly describe the event of interest. The 
conventional endpoint in survival analysis is death. Unlike in situations where logistic regression 
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might be used, this is not death within a fixed interval; rather, the outcome is the time to the event. 
However, survival analysis can also be applied to other events; for example, major adverse cardiac and 50 
cerebrovascular events (MACCE), which is a combined endpoint of all-cause death, stroke, 
myocardial infarction (MI) and repeat revascularisation. This does not change anything in the analysis 
or graphical representation, but outcomes are then described as disease-free survival or cumulative 
event rate. However, when analysing non-terminal events, researchers should be aware of the concept 
of competing risks [9]. 55 
Follow-up period. It is essential to use a clinically appropriate follow-up period when 
analysing survival data of two different treatment-groups. For instance, a comparison of PCI versus 
CABG will be biased towards PCI if the follow-up period is too short to capture all relevant events of 
both treatment strategies. 
Follow-up data is difficult to collect: once the patient is discharged from the hospital, it creates 60 
additional work to track their status. Consequently, it is essential to describe the method of collecting 
follow-up data [10]. It is important to recognise that in models such as the Cox regression model, the 
number of events is of most importance rather than the number of subjects; hence an appropriate 
follow-up time must be considered. Moreover, the follow-up time distribution should be appropriately 
summarised, including the median follow-up time (with clarification of which method was used [11]), 65 
key dates (e.g. of final follow-up), the number of subjects lost to follow-up, and the number of events 
observed [8, 12]. When plotting Kaplan-Meier survival estimates (see below), another useful summary 
is the number of patients still at risk at a set of discrete time points (Figure 1B). 
 
Visualising survival data 70 
Life-table. A life-table is the most basic form of survival analysis and is instrumental in 
explaining how censoring is handled [13]. To construct a life-table, the follow-up time is split into 
discrete time periods. For each time period, the numbers at risk are calculated by accounting for the 
subjects who died and were censored. These calculations result in an estimated survival probability for 
each time period [14]. 75 
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Kaplan-Meier estimator. The standard graphical plot of the cumulative survival probability 
during a defined follow-up period is the Kaplan-Meier plot, which is based on the non-parametric 
product-limit estimator [1]. The product-limit estimator can effectively be considered as the 
generalisation of the life table approach to each unique continuous event time. Steps in the Kaplan-
Meier plot occur at each unique event time. All the necessary and essential information has to be 80 
clearly displayed to the reader. Example Kaplan-Meier plots that either do or do not achieve 
acceptable reporting standards for the EJCTS and ICVTS are presented in Figure 1 [12]. Kaplan-
Meier plots may also be presented as downward sloping (i.e. cumulative survival; Figure 1) or upward 
sloping (i.e. cumulative event rate; Figure 2). The latter has been advocated by experts in biostatistics 
[15]. Moreover, always be aware of a potential break in the vertical axis. In addition, to avoid 85 
misinterpretation of the graphs, authors might consider halting the Kaplan-Meier estimates when only 
a small proportion (e.g. 10%) of patients are at risk [15]. This is because the eye is drawn to the right 
hand-side of the Kaplan-Meier plot, which is where the uncertainty is greatest due to only a small 
remaining number of patients at risk. However, this restriction is only for the graph; all data and 
events should be retained for analysis. 90 
 
Comparing survival data  
The log-rank test and the Cox proportional hazards model are the two most commonly used tests for 
comparing differences in survival data between study groups. It is important to note that the factor on 
which comparison is to be made is recorded at baseline, i.e. before the time origin. It is not possible to 95 
‘reach’ forward in time. A classic example involves heart transplantation. In the Stanford Heart 
Transplant Study, patients who were eligible for transplantation were followed until death or 
censorship [16]. The objective of the study was to assess whether patients who received a transplant 
live longer than those not receiving a transplant. Comparing the survival distributions between those 
who received a transplant at some point and those who did not is, however, not appropriate. Patients 100 
who received a transplant must have lived until the point of transplantation, and therefore must have 
contributed to survival time in the non-transplant group [17]. In short, transplantation status is not 
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known at the time of eligibility; hence, no conditioning on this variable should be made in advance. In 
such situations, one might consider i) including a time-dependent covariate [18]; ii) using a landmark 
analysis [19]; or iii) not including measurements which occurred after the time origin. However, the 105 
choice of approach would depend on the application. 
Log-rank test. The log-rank test is a standard nonparametric method for unadjusted 
univariable comparison of survival data between two (or more) study groups [2]. The log-rank test 
assumes that censoring is unrelated to prognosis and compares the complete survival distributions. The 
null hypothesis is that there are no differences in survival distributions between study groups. When 110 
the resulting P-value from the log-rank test is small, the null hypothesis should be rejected. 
Notwithstanding the ubiquity of the log-rank test, several variations have been proposed based on the 
inclusion of weights. These include the Wilcoxon, Tarone-Ware, Peto, and Flemington-Harrington 
tests [17]. 
The Cox proportional hazards model. The Cox proportional hazards model is widely used 115 
for the adjusted comparison of survival data [3]. Like other types of regression models, adjustment can 
be univariable or multivariable. In the latter case, it is therefore possible to assess the independent 
association of a specific variable of interest (e.g. treatment arm) on survival whilst adjusting for other 
confounders. The term hazard refers to the risk of an event occurring per unit of time, conditional on 
the subject having survived up to that time. The model is formulated in terms of the hazard function, 120 
ℎ𝑖(𝑡), as follows 
log ℎ𝑖(𝑡) = log ℎ0(𝑡) + 𝛽1𝑥1𝑖 + 𝛽2𝑥2𝑖 + ⋯ + 𝛽𝑝𝑥𝑝𝑖, 
where ℎ0(𝑡) is the baseline hazard (a function of time), which by virtue of the partial likelihood 
estimation method developed by Cox, we can leave unspecified, hence the name semiparametric 
model. The measured baseline values for subject i are  𝑥1𝑖, 𝑥2𝑖, … , 𝑥3𝑖 and associated with coefficients 125 
𝛽1, 𝛽2, … , 𝛽𝑝, respectively. The coefficients are estimated, but usually reported as exponentiated 
values, i.e. exp(𝛽𝑗), called hazard ratios (HR), which like other regression models, are reported 
together with confidence intervals and P-values, allowing for inference. If a HR is significantly >1, 
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then we can conclude that an increase in that risk factor corresponds to an increase in the event hazard, 
which in turn decreases the length of survival. 130 
Assumptions in the Cox proportional hazards model. In the Cox proportional hazards (PH) 
model, the HR is assumed to be constant over time [7, 20]. Methods for verifying this important 
assumption include i) smoothed scaled Schoenfeld residual plots, ii) complementary Kaplan-Meier 
plots, iii) the Grambsch-Therneau test based on the Schoenfeld residuals, or iv) including time-
dependent coefficients into the regression model [21]. In the case of crossing survival estimates, which 135 
is not uncommon in comparisons between interventional and surgical procedures, the analysis should 
be modified to compensate for non-PH. If the variable that violates the proportionality assumption is 
categorical and not of inferential interest, then the simplest approach is to use it to stratify the baseline 
hazard. Alternative options include: dividing the follow-up time into intervals for which the hazard 
ratios are known to be proportional [21]; fitting an extended Cox model [21, 22]; fitting a parametric 140 
survival model that does not rely on the PH assumption; or interpret the HR as an average HR. More 
recently, it has been proposed to compute the restricted mean survival time instead [23]. 
Comparison with the general population. Occasionally, an interest exists to compare the 
survival distribution of a study cohort to that of a general population. The standardized mortality ratio 
describes the number of observed deaths (O) in relation to the number of expected deaths (E), 145 
retrieved from actuarial tables. To allow an appropriate interpretation of this O/E-ratio, it needs to be 
matched with respect to age, sex, ethnicity and socio-economic aspects. An O/E-ratio of > 1 indicates 
the observed mortality is higher than the expected mortality. Testing for significant differences in 
survival between the study and general population is challenging [24], but it can be performed by a 
one-sided log-rank test [25]. 150 
 
Example 
To illustrate the concepts and methods described in this article, survival data from the “Synergy 
between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery” (SYNTAX) trial are 
presented. In this trial, patients with multi-vessel coronary artery disease were randomized to PCI with 155 
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paclitaxel-eluting stents or CABG [26]. The five-year outcomes in subgroups with (n = 452) or 
without (n = 1348) diabetes were compared for MACCE. Five-year clinical follow-up was performed 
by a clinic visit or telephone call in 86.5% of CABG patients and 94.5% of PCI patients. The follow-
up was complete (clinical follow-up or death) in 88.0% (CABG) and 95.2% (PCI). 
Event rates were estimated with Kaplan-Meier estimators (Figure 2). The survival at 5-years 160 
in the diabetic PCI arm was 88.0% and 89.1% for the diabetic CABG arm (log-rank test P=0.48). An 
unadjusted HR of 1.81 (CI 95% [1.31 to 2.48], P<0.001) suggests that a diabetic patient undergoing 
PCI has a 1.81 times significantly increased hazard of developing MACCE compared to a diabetic 
patient undergoing CABG. 
 165 
Survival analysis software 
Most of the described survival analyses can be executed using straightforward packages in software 
programs, including R (R Development Core Team, Vienna, Austria) using the ‘survival’ package; 
SPSS (IBM Corp., Armonk, New York, USA) using the ‘Survival’ tab from the ‘Analyse’ menu; and 
Stata (StataCorp., College Station, Texas, USA), e.g. using the ‘st’ and ‘stcox’ commands. For each 170 
subject, the data required to implement software analyses are i) a continuous time observation which 
measures the time until an event or when a subject drops out of the study (censoring) and ii) a 
dichotomous observation describing whether the subject experienced the event or not (usually coded 1 
and 0, respectively). Additional columns for baseline data (e.g. treatment groups, gender, age, etc.) can 
also be included for log-rank tests and Cox proportional hazards regression. As for regression 175 
modelling in general, development must consider which (and how many) covariates to include, the 
functional form and interaction terms. 
 
Conclusion 
Survival analysis concentrates on the time until an event of interest. Specific methods are used to 180 
analyse and compare survival data, including Kaplan-Meier method, the log-rank-test and the Cox 
proportional hazards model. When fitting a Cox regression model, it is crucial to evaluate whether the 
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proportional hazards assumption is met. Here, only the fundamentals routinely used by cardiothoracic 
surgeons in their daily research are described, and this paper serves as a guide for publishing their 
analysis in EJCTS and ICVTS. Yet of course, advanced survival analysis methods are available. These 185 
include alternative regression models to the Cox model, inclusion of time-varying covariates, 
competing risks data, recurrent events data, frailty models (i.e. the inclusion of random effects), and 
the joint modelling of survival and longitudinal data [9, 20, 27-29]. 
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FIGURE LEGENDS 
Figure 1. Two examples of Kaplan-Meier estimates in patients with advanced lung cancer. 
Panel A: a figure that lacks vital information or does not adhere to the EJCTS and ICVTS reporting 195 
guidelines. Panel B: a publication-ready figure. The plot in Panel A is not suitable for publishing in 
EJCTS or ICVTS; for example, it i) lacks a legend clarifying which group is represented by each line, 
ii) has no units on the horizontal and vertical axes, iii) uses time-intervals of 200 days that are difficult 
to interpret, iv) does not display a table giving the number of patients at risk at different time points, 
and v) does not indicate the censoring times. In contrast, the plot in Panel B demonstrates an 200 
appropriate way of reporting. In Panel B, dotted lines denote 95% confidence bands, and tick marks 
denote censoring times. Reproduced with permission from Hickey et al. [12] and Oxford University 
Press. 
 
Figure 2. Five-year outcomes of PCI versus CABG in diabetic patients in the SYNTAX trial. 205 
Kaplan–Meier estimates of major adverse cardiac or cerebrovascular events  (MACCE) in diabetic 
patients undergoing PCI versus CABG. Coronary artery bypass grafting (dotted line); PCI: 
percutaneous coronary intervention (solid line). Reproduced with permission from Kappetein A.P. et 
al. [26] and Oxford University Press. 
 210 
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FIGURES 
Figure 1. 
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Figure 2. 
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